About Codexis, Inc.
https://www.codexis.comCodexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.
CEO
Stephen George Dilly MBBS,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 65
Ratings Snapshot
Rating : D+
Price Target
Institutional Ownership
OPALEYE MANAGEMENT INC.
Shares:12.79M
Value:$22.78M
BLACKROCK, INC.
Shares:7.14M
Value:$12.72M
BLACKROCK INC.
Shares:6.79M
Value:$12.09M
Summary
Showing Top 3 of 165
About Codexis, Inc.
https://www.codexis.comCodexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.6M ▼ | $25.09M ▼ | $-19.61M ▼ | -228.05% ▼ | $-0.22 ▼ | $-16.26M ▼ |
| Q2-2025 | $15.33M ▲ | $26.09M ▲ | $-13.27M ▲ | -86.59% ▲ | $-0.16 ▲ | $-11.96M ▲ |
| Q1-2025 | $7.54M ▼ | $25.3M ▲ | $-20.69M ▼ | -274.27% ▼ | $-0.25 ▼ | $-18.77M ▼ |
| Q4-2024 | $21.46M ▲ | $25.15M ▲ | $-10.38M ▲ | -48.35% ▲ | $-0.13 ▲ | $-8.28M ▲ |
| Q3-2024 | $12.83M | $25.07M | $-20.64M | -160.84% | $-0.29 | $-13.68M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $59.19M ▼ | $123.96M ▼ | $85.42M ▲ | $38.54M ▼ |
| Q2-2025 | $66.33M ▲ | $138.25M ▲ | $82.61M ▲ | $55.63M ▲ |
| Q1-2025 | $59.78M ▼ | $128.89M ▼ | $79.26M ▼ | $49.63M ▼ |
| Q4-2024 | $73.46M ▼ | $149.01M ▲ | $82.08M ▲ | $66.93M ▼ |
| Q3-2024 | $90.25M | $148.18M | $74.78M | $73.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-19.61M ▼ | $-7.7M ▲ | $6.39M ▲ | $-111K ▼ | $3.54M ▼ | $-7.88M ▲ |
| Q2-2025 | $-13.27M ▲ | $-17.97M ▼ | $-367K ▼ | $26.77M ▲ | $8.44M ▲ | $-20.48M ▼ |
| Q1-2025 | $-20.69M ▼ | $-13.8M ▲ | $11.77M ▲ | $1.08M ▼ | $-944K ▲ | $-15.05M ▲ |
| Q4-2024 | $-10.38M ▲ | $-16.47M ▼ | $-2.86M ▼ | $1.13M ▼ | $-18.2M ▼ | $-18.24M ▼ |
| Q3-2024 | $-20.64M | $-12.98M | $1.53M | $30.31M | $18.85M | $-13.99M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $30.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Research and Development Revenue | $20.00M ▲ | $0 ▼ | $10.00M ▲ | $0 ▼ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Americas | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $0 ▼ |
 APAC | $0 ▲ | $0 ▲ | $10.00M ▲ | $10.00M ▲ |
 EMEA | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Stephen George Dilly MBBS,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 65
Ratings Snapshot
Rating : D+
Price Target
Institutional Ownership
OPALEYE MANAGEMENT INC.
Shares:12.79M
Value:$22.78M
BLACKROCK, INC.
Shares:7.14M
Value:$12.72M
BLACKROCK INC.
Shares:6.79M
Value:$12.09M
Summary
Showing Top 3 of 165